Latest news with #ShilpaMedicare
Business Upturn
28-05-2025
- Business
- Business Upturn
Antique cuts target on Shilpa Medicare to Rs 1,090, retains ‘Buy' on long-term monetization potential
By News Desk Published on May 28, 2025, 08:31 IST Antique Broking has maintained a Buy rating on Shilpa Medicare (SLPA) while cutting the target price to ₹1,090 from ₹1,525, citing strong revenue growth in Q4FY25 but tempered expectations for the near term due to regulatory delays and cost pressures. Shilpa Medicare reported a 13% year-on-year increase in Q4FY25 revenue to ₹3,308 million, driven by an impressive 73% growth in the Finished Dosage Form (FDF) segment. The brokerage highlighted SLPA's exclusive licensing deal with Orion for recombinant human albumin in Europe, which holds significant commercial potential. Milestone-linked payments under this agreement are expected to begin in FY26. However, the firm flagged approval delays for Unicycive's NDA for Oxylanthanum Carbonate (OLC), a partnered product. The delay, caused by manufacturing issues, is expected to push associated revenues to FY27. Antique has cut its FY26/27 revenue estimates by 16%/20%, moderating its assumptions for growth in the API business and adjusting expectations for 505(b)(2) opportunities. It also lowered EBITDA margin assumptions to reflect persistent higher operating expenses. Despite these adjustments, the brokerage continues to see strong monetization potential in SLPA's product pipeline, positioning it well for medium to long-term growth. Disclaimer: The views and recommendations expressed above are those of the brokerage firm. Business Upturn does not endorse or offer any investment advice. News desk at
Business Standard
27-05-2025
- Business
- Business Standard
Shilpa Medicare slides after Q4 PAT drop 41% YoY to Rs 15-cr
Shilpa Medicare declined 1.25% to Rs 878.35 after the company's consolidated net profit fell 40.77% to Rs 14.51 crore while revenue from operations rose 13.40% to Rs 330.80 crore in Q4 FY25 over Q4 FY24. Profit before exceptional items and tax stood at Rs 43.35 crore in Q4 FY25, up 100.88% from Rs 21.58 crore posted in the corresponding quarter previous year. The firm reported exceptional items of Rs 28.08 crore during the quarter. EBITDA jumped 15% to Rs 84 crore in Q4 FY25 from Rs 73 crore in Q4 FY24. EBITDA margin remained constant at 25% in Q4 FY25 compared to Q4 FY24. Total expenses were up by 9.12% year on year to Rs 297.32 crore in the quarter ended 31 March 2025. The cost of materials consumed stood at Rs 85.14 crore (down 15.83% YoY), while employee benefits expense was at Rs 70.93 crore (up 6.72% YoY). On a full-year basis, the company's consolidated net profit surged 145.65% to Rs 78.29 crore on an 11.70% jump in revenue from operations to Rs 1,286.41 crore in FY25 over FY24. Vishnukant Bhutada, managing director of Shilpa Medicare, said, FY25 performance reflects our pursuit of a differentiated business model enabling us to grow with improved profitability. In FY25, Shilpa Medicare has emerged stronger, turning years of strategic investments and relentless perseverance into remarkable achievements in differentiated initiatives like the launch of two NDAs in US market, filing of transdermal patch product in EU, SEC clearance of Nor-UDCA in India and OLC filing by our partner with US FDA. Our unwavering commitment to innovation and R&D has borne fruit, with a significant breakthrough in out-licensing our flagship productrecombinant human albuminfor commercialization across EU region in strategic partnership with Orion Corporation. Besides this, we also saw a very successful year on the regulatory front, as we received EIR for our API Unit 1, along with EU GMP certifications for our FDF Unit 6 (having ODF & TDP manufacturing capabilities) and for our Biologics unit. I believe this will help in enabling us to further scale up our biologics CDMO platform and give us the opportunity to monetize our biosimilar pipeline for large regulated markets. With asset utilization improvement across key verticals, we remain confident of delivering improved profitability in FY26. As we advance, we remain committed to leveraging our R&D strengths, regulatory compliance, and operational agility to create long-term value. Meanwhile, the companys board has decided to pay a dividend of Rs 1 per equity share for FY 2024-2025. The final dividend, if approved by the members at the ensuing Annual General Meeting, shall be paid within the statutory timelines prescribed under applicable laws. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India.
Yahoo
27-05-2025
- Business
- Yahoo
Shilpa Medicare Ltd (BOM:530549) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Release Date: May 26, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Shilpa Medicare Ltd (BOM:530549) reported a 15% year-on-year growth in total revenue for the quarter, reaching INR 338 crore. The company's gross margin improved by 200 basis points to 69% compared to the same quarter last year. The formulation business saw a significant 38% year-on-year growth, driven by limited competition in the European market for certain products. The biologics division is expected to double its sales in the current financial year due to additional indications approval. Shilpa Medicare Ltd (BOM:530549) successfully completed USFDA inspections for its API business units, receiving EIR with VI status for one unit. The company's licensing revenue decreased from INR 34 crore in Q4 FY24 to INR 24 crore in Q4 FY25, indicating variability in this income stream. There is a delay in the start of phase 3 clinical trials for a key biologic product, potentially impacting timelines. The US FDA import alert on the formulation manufacturing facility remains unresolved, affecting potential margin improvements. The API business has experienced flat or declining growth over the past year, although future growth is anticipated. The company faces challenges in predicting consistent licensing revenue due to its lumpiness and dependency on milestone achievements. Warning! GuruFocus has detected 3 Warning Sign with BOM:530549. Q: Can you provide a breakdown of the biologics segment revenue, specifically how much was contributed by Atalia and the CDMO segment? A: The biologics segment recorded a revenue of 15 to 20 crores from Atalia in the last financial year, which is expected to double in FY26. The rest of the revenue comes from CDMO and licensing, and we can provide exact numbers later. - Executive Director Q: With the official launch of Bozitinib in the US market, can we expect a faster ramp-up in sales compared to Primitex? A: Unlike Primitex, which faced competition from Eagle's product, Bozitinib has no significant competition in the market. We are the only product with subcutaneous approval, which should facilitate a quicker market uptake. - Executive Director Q: Regarding the partnership with Orient for recombinant albumin, what kind of milestone fees can we expect, and is there a delay in starting phase 3 trials? A: Financial details are confidential, but the deal includes milestones spread across signing, filing, approval, and launch. There might be a delay of 1-2 quarters in starting phase 3 trials as we aim to supply from our new facility. - Executive Director Q: Have you received any final inspection dates from the USFDA regarding the import alert, and how will this affect margins? A: We have completed remediation activities, and the FDA is likely to conduct a surprise inspection this financial year. Margin improvement will not be significant from CMO cost savings but will come from increased CDMO revenue and product approvals. - Executive Director Q: Can you explain the significance of the EU GMP approval for the biosimilar plant and its impact on revenue? A: The EU GMP approval is significant as it opens doors for CDMO services in Europe. We expect an increase in CDMO revenue, although the exact impact will depend on the number of contracts secured. - Executive Director For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
27-05-2025
- Business
- Business Standard
Shilpa Medicare consolidated net profit declines 40.78% in the March 2025 quarter
Sales rise 13.41% to Rs 330.80 crore Net profit of Shilpa Medicare declined 40.78% to Rs 14.51 crore in the quarter ended March 2025 as against Rs 24.50 crore during the previous quarter ended March 2024. Sales rose 13.41% to Rs 330.80 crore in the quarter ended March 2025 as against Rs 291.69 crore during the previous quarter ended March 2024. For the full year,net profit rose 145.65% to Rs 78.29 crore in the year ended March 2025 as against Rs 31.87 crore during the previous year ended March 2024. Sales rose 11.71% to Rs 1286.41 crore in the year ended March 2025 as against Rs 1151.60 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 330.80291.69 13 1286.411151.60 12 OPM % 23.2123.97 - 24.5520.82 - PBDT 72.1548.21 50 263.41156.07 69 PBT 43.3521.58 101 150.4148.20 212 NP 14.5124.50 -41 78.2931.87 146
Economic Times
26-05-2025
- Automotive
- Economic Times
ET Market Watch: Trump pauses tariffs, markets boom! Nifty at 25,000; Sensex surges 455 points
Transcript Hi, you're listening to ET Markets Radio, I am your host Neha V Mahajan. Welcome to a fresh episode of ET Market Watch -- where we bring you the latest news from the world of stock markets every single day. Let's get to it:Markets hit new milestones! After so long -- Nifty closed above 25,000 level while the Sensex ended the day up 455 points at 82,176 – thanks to a solid rally in auto, IT, and defence triggered the rally?US President Donald Trump paused the 50% tariffs on the EU, easing global trade tensions. That move sent auto stocks soaring — both globally and on Dalal gainersBEML surged 11.5%, Shilpa Medicare jumped 13%, and Lloyds Enterprises gained over 11%. In the Nifty 50 pack, Bajaj Auto, JSW Steel, and M&M led the charge, while Kotak Bank and UltraTech Cement viewEvery major sector ended in the green! Nifty Auto rose 1.14%, IT was up 1.03%, Metal rose 1% and FMCG ended 0.99% watch:The rupee strengthened to 85.08/USD, after touching a 2-week high of 84.79. Gains were capped as the dollar index cues: MIXEDJapan's Nikkei rallied 1%STOXX 600 in Europe up 1%But Hong Kong's Hang Seng fell 1.4%Crude check:Oil prices edged up as tariff fears eased:Brent at $65.17, up 0.6% while US WTI ended at $61.86, up 0.5%. The extension of trade talks eased fears of a slowdown in fuel demand.
